Rising number of Chronic Diseases are driving the growth of ASEAN Health Screening Market

The increasing prevalence of chronic diseases in ASEAN is a primary driver for the health screening market. As lifestyles change and populations’ age, chronic conditions such as cardiovascular diseases, diabetes, and cancer are becoming more common. This trend has spurred demand for regular health screenings, early detection services, and preventive healthcare measures. Governments and healthcare providers are expanding screening programs and investing in advanced diagnostic technologies to address these health challenges effectively. As the burden of chronic diseases continues to grow, the ASEAN health screening market is expected to expand further to meet the rising healthcare needs of the population. For instance, in September 2022, a report by WHO, “WHO South-East Asia Region to accelerate progress for NCD prevention and control” showing that progress for prevention and control of non-communicable diseases, including oral and eye care. Mentioned, Noncommunicable diseases, including cardiovascular diseases, cancers, chronic respiratory disease and diabetes, account for almost two-thirds of all deaths in the WHO South-East Asian Region. Nearly half of these deaths occurred prematurely between the ages of 30 and 69 years in 2021.

As the prevalence of conditions such as diabetes, cardiovascular diseases, and cancer continues to increase, expanding access to comprehensive health screenings becomes crucial for managing these health challenges effectively. Investing in advanced diagnostic technologies, increasing public health awareness, and strengthening healthcare infrastructure will be essential in addressing the growing burden of chronic diseases and improving overall health outcomes in the region.

Access Full Report @ https://www.databridgemarketresearch.com/ko/reports/asean-health-screening-market

Data Bridge Market Research analyzes that the ASEAN Health Screening Market is expected to grow at a CAGR of 13.5% in the forecast period of 2024 to 2031 and is expected to reach USD 47,078.82 million by 2031 from USD 17,697.22 million in 2023. The cholesterol tests segment is projected to propel the market growth due to the rising adoption of cholesterol test.

Key Findings of the Study

Rising Number of Chronic Diseases for Core Banking Solutions

Report Scope and Market Segmentation

Segment Analysis

ASEAN Health Screening market is segmented into seven notable segments based on test type, application, panel type, care/facility, user, customer income, and provider.

• Based on test type, the market is segmented into into cholesterol tests, diabetes test, cancer tests, general check up test, STD's, blood pressure test, and others

In 2024, the cholesterol tests segment of the test type segment is expected to dominate the market

In 2024, the cholesterol tests segment is expected to dominate the market with a market share of 28.61% due to the rising demand of cholesterol test.

• Based on application, the market is segmented into cardiovascular disease, metabolic disorders, oncology, inflammatory conditions, musculoskeletal disorders, neurological conditions, hepatitis-c complications, immunology-related conditions, and others

In 2024, the cardiovascular disease segment of the offering segment is expected to dominate the market

In 2024, the cardiovascular disease segment is expected to dominate the market with a market share of 33.50% due to the high prevalence of cardiac diseases.

• Based on panel type, the market is segmented into multi-test panels and single test panels. In 2024, the multi-test panels segment is expected to dominate the market with a market share of 78.65%
• Based on care/facility, the market is segmented into integrated and standalone. In 2024, the integrated segment is expected to dominate the market with a market share of 60.85%
• Based on user, the market is segmented into domestic user and medical tourist. In 2024, the integrated segment is expected to dominate the market with a market share of 87.87%
• Based on customer income, the market is segmented into upper class, medium class and lower class. In 2024, the upper class segment is expected to dominate the market with a market share of 59.11%
• Based on provider, the market is segmented into hospitals, clinics, nursing facilities, rehabilitation centers, diagnostic laboratories and others. In 2024, the hospitals segment is expected to dominate the market with a market share of 28.28%

Major Players

Data Bridge Market Research recognizes the following companies as the major ASEAN health screening market players in the market that include Fullerton Health Corporation Limited (Singapore), Mount Alvernia Hospital (Singapore), PT Prodia Widyahusada Tbk (Indonesia), Raffles Medical Group (Singapore), Icon Group (Australia), The Farrer Park Company (Singapore), Parkway Holdings Limited(Singapore), PT Siloam International Hospitals Tbk (Indonesia), Mount Elizabeth Hospital (Singapore), and SingHealth Group (Singapore) among others.

Market Development

• In June 2024, Prodia Diagnostic Line hosted topping-off for new production facility, targeting TKDN above 60%. PT Prodia Diagnostic Line (Proline), sister company of PT Prodia Widyahusada Tbk (PRDA) which is engaged in manufacturing reagents and test equipment, was held the topping off of its newest production facility building in the Jababeka area, Cikarang. This new factory is projected to increase the annual production capacity of in vitro diagnostic (IVD) products by three times. For example, the capacity for hematology products from 60 thousand packs to 180 thousand packs, and laboratory instrument assembly from 1000 to 4000 units
• In February 2023, Farrer Park Hospital initiated a clinical collaboration with Allegiant Regional Care (ARC) Hospitals to enhance continuing medical education for specialists and physicians, aiming to improve patient care and foster clinical innovation. It enhanced the company's ability to improve patient care and foster clinical innovation through advanced continuing medical education for specialists and physicians
• In August 2022, Fullerton Health completed merger led by RRJ Capital; Stronger Balance Sheet and New Corporate structure propelled the post-pandemic growth opportunities. Fullerton Health Corporation Limited (“Fullerton Health” or the “Company”) announced that it completed a merger led by RRJ Capital (“RRJ”) involving an equity injection by the private equity firm and a senior loan totalling USD 390 million. The merger delivered a stronger balance sheet and a new capital structure which propelled post-pandemic growth opportunities for the pan-Asian healthcare provider
• In June 2022, Farrer Park Hospital launched an AI-assisted colorectal screening service to enhance detection, classification, and surveillance of colorectal polyps and cancer, aiming to advance patient care and diagnostic accuracy
• In June 2021, Raffles Medical Group and China Life Healthcare Investment Company Limited (CLHI) signed a Memorandum of Understanding, establishing a strategic partnership between CLHI and Singapore’s largest private healthcare provider, which enhanced the group's international reach and collaboration
• In September 2020, the Farrer Park Company Pte Ltd secured a USD 120 million green loan from United Overseas Bank Limited (UOB), the first for a healthcare facility in Singapore, underpinning sustainability efforts. The funds were expected to refinance Connexion, Singapore's pioneering integrated healthcare and hospitality complex, enhancing operational efficiency and sustainability initiatives

Regional Analysis

Geographically, the countries covered in the ASEAN health screening market report are the India, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Cambodia, Brunei, Burma, and Laos.

As per Data Bridge Market Research analysis:

For more detailed information about the ASEAN Health Screening market report, click here – https://www.databridgemarketresearch.com/ko/reports/asean-health-screening-market